The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
FDA approves subcutaneous Opdivo, enhancing cancer treatment with similar efficacy to intravenous form and improved patient ...
The FDA approved an injectable version of Opdivo, a cancer drug by Bristol Myers Squibb. Axsome plans to seek approval for ...
Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...
Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...
FDA Approval of Opdivo Injection Sparks Hope for Cancer Patients with Revolutionary Treatment Update
In a significant advancement for cancer care, the U.S. Food and Drug Administration (FDA) has approved an injectable version ...
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
The FDA approves an injectable Opdivo cancer drug; Axsome seeks approval for an Alzheimer's drug amid mixed results; Hain ...
BMSs Opdivo gains FDA approval for faster subcutaneous cancer treatment BMS secures FDA nod for rapid cancer treatment ...
The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback